Company / R&D Expense
Neurocrine Biosciences R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.0B
FY2025
5-year range
$328.1M / $1.0B
FY2021-FY2025
Trend
+38.9%
vs FY2024
Sector context
#16 of 209
Health Care
What the data says
Among 209 Health Care companies, Neurocrine Biosciences is in the top 8% for r&d expense. R&D Expense has increased for 8 consecutive years, from $94M in FY2016 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +29.9%. Top quartile in the Health Care sector.
Improved from $565M to $1.0B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +29.9%
- 5-Year CAGR
- +29.9%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 209This company $1.0B Sector average $647.6M
▼
+56.8% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +29.9%, indicating consistent growth.
- In FY2025, r&d expense increased 38.9% year-over-year.
- Ranks #16 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | +38.9% |
| FY2024 | $731.1M | +29.4% |
| FY2023 | $565.0M | +21.8% |
| FY2022 | $463.8M | +41.4% |
| FY2021 | $328.1M | +19.3% |
| FY2020 | $275.0M | - |
| FY2019 | - | - |
| FY2018 | $160.5M | +31.8% |
| FY2017 | $121.8M | +29.2% |
| FY2016 | $94.3M | +15.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026